Visudyne Manufacturer QLT Must Pay Sales Royalties To AMD Therapy Patent Inventors
This article was originally published in The Pink Sheet Daily
Court must still decide whether Massachusetts Ear and Eye Infirmary, which won the patent case, is entitled to payments on past sales of the Novartis-marketed eye treatment.
You may also be interested in...
Ongoing Macugen trials look promising, but OSI chooses to put its R&D funds into diabetes and oncology businesses, CEO tells analysts.
The company recorded $153 mil. in sales for the macular degeneration product in its first full quarter on the market.
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.